Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

In This Issue

J Immunol March 1, 2014, 192 (5) 1995-1996; DOI: https://doi.org/10.4049/jimmunol.1490001
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Modulating MAC in Traumatic Brain Injury

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

The complement system has been identified as an early mediator of neuroinflammation and neuropathology following traumatic brain injury (TBI). Therapies to improve neurologic outcomes in TBI patients have focused on broad inhibition of the complement cascade, which can limit effective immune responses against infections in TBI patients. To evaluate the role of the membrane attack complex (MAC) of the complement system in TBI, Fluiter et al. (p. 2339) used a mouse model of mild and severe closed head injury. Immunostaining of injured brain tissue with C9, a marker of MAC deposition, and markers of activated microglia/macrophages demonstrated that severe TBI resulted in increases in MAC deposition and inflammation relative to both mild TBI and uninjured mice. To block MAC formation without altering early complement activation, the authors designed antisense oligonucleotides targeting C6 production and compared its therapeutic efficacy to the Ornithodoros moubata complement inhibitor (OmCI), a known inhibitor of C5 activation. Pretreatment of TBI mice with C6 antisense or treatment with OmCI up to 15 min post-TBI reduced weight loss, neuroaxonal apoptosis and loss, MAC deposition, and neuroinflammation in the brain and improved neurologic performance at 72 h postinjury. This study demonstrates that MAC inhibition can improve neurologic recovery after TBI and proposes a novel therapeutic target for the treatment of TBI.

Supercharged Neutrophil Responses

The “genomic storm” following traumatic injury is characterized by a modulation of both innate and adaptive immunity genes, leading to suppression of adaptive immunity, enhancement of innate immunity, and significant changes in hematopoiesis, marked by an expansion of myeloid cells. Although traumatic injury is thought to have an overall suppressive effect on the immune system, Gardner et al. (p. 2405) demonstrated that thermal injury conferred protection against lethal Klebsiella pneumoniae challenge. Burn-injured mice (15% total body surface burn) had a marked survival advantage over sham-injured mice when challenged with K. pneumoniae 7 d postinjury. The resistance to infection in burn-injured mice was accompanied by a significant neutrophilic response in the lungs and blood, and protection could be completely reversed by treatment with a neutrophil-depleting Ab. A significant shift toward CD11b+ myeloid lineage cells in the bone marrow was accompanied by an increase in serum G-CSF and IL-6, concomitant with activation of the STAT3 pathway in inoculated burn-injured compared with sham-injured mice. Neutralization of G-CSF blocked 80% of the thermal-injury-induced STAT3 activation in bone marrow progenitor cells, thereby preventing neutrophilia. Conversely, administration of recombinant G-CSF increased neutrophil numbers and conferred a survival advantage in K. pneumoniae-inoculated mice. Taken together, these data suggest a key role for the G-CSF/STAT3 axis in neutrophil responses against infection following traumatic injury.

E2A Fights Allelic Exclusion

It is known that a negative feedback loop initiated by pre-BCR activation and Ca2+ signaling is required for allelic exclusion to occur during V(D)J recombination of Igh genes, but the details of the allelic exclusion molecular mechanism remain an enigma. Hauser et al. (p. 2460) set out to determine if regulation of E2A, a transcription factor known to be expressed during V(D)J recombination, by the Ca2+-sensor protein calmodulin plays a role in this process. To do this, the authors adoptively transferred wild-type (WT) or calmodulin-resistant E2A-expressing bone marrow cells from E2A+/− C57BL/6 X BALB/c F1 mice into lethally-irradiated recipients capable of expressing IgM allotypes from either parent strain. They found that the propensity of B cells from these mice to express both the BALB/c and C57BL/6 allotypes of IgM on the same cell statistically increased in calmodulin-resistant E2A-expressing B cells, suggesting that these cells are defective in allelic exclusion. Pre-BCR signaling-initiated inhibition of transcription factors involved in V(D)J recombination was reduced in calmodulin-resistant E2A-expressing B cells, indicating that regulation of these molecules is dependent on E2A sensitivity to calmodulin. Data from chromatin immunoprecipitation analyses suggested that the calmodulin-resistant E2A sequestered the recombination complex on the Igh locus, whereas WT E2A allowed this complex to be released. Together, these results suggest that calmodulin regulation of E2A plays an integral role in the allelic exclusion process.

IgA Helps NET Bacteria

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

The expulsion of neutrophil extracellular traps (NETs), which trap and kill pathogens, leads to neutrophil cell death, referred to as NETosis. Previous work by Aleyd et al. (p. 2374) demonstrated that the IgA Fc receptor (FcαRI) triggered the activation of polymorphonuclear cells (PMNs), such as neutrophils, leading to enhanced phagocytosis of IgA-opsonized bacteria and PMN trafficking. In this study, the authors investigated whether FcαRI promotes NET formation. Stimulation of PMNs with Staphylococcus aureus in the presence of serum IgA led to an expansion in PMN size and degradation which increased over time relative to unstimulated PMNs or PMNs stimulated in the absence of IgA. Real time video recordings of unstimulated and S. aureus-stimulated PMNs labeled with Organelle ID, which fluorescently labels organelles with different colors, demonstrated hallmarks of apoptosis, such as Annexin-V staining followed by expression the cell death marker 7-AAD. In contrast, PMNs incubated with IgA-opsonized S. aureus demonstrated diffusion of nuclear contents throughout the cell, cell membrane disintegration, the expression of 7-AAD without Annexin-V, and the formation of NETs. Incubation of PMNs with IgA-coated beads, but not control BSA-coated beads, increased PMN phagocytosis and NET induction which could be abrogated by blocking either FcαRI or ROS production. The stimulation of phagocytosis and NETosis by IgA suggests a mechanism by which IgA plays a prominent role in mucosal inflammatory responses.

Binding Potential TAPped

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

TAP is a heterodimer composed of two protein components, TAP1 and TAP2, and has essential functions in the MHC I Ag processing pathway, one of which is to interact with the chaperone protein tapasin to facilitate loading of peptide Ag onto MHC I molecules. Tapasin promotes TAP stability and has three known binding sites on TAP1, two in the N-terminus and one in the core transmembrane domain (coreTMD), but it is unclear which of these three sites are required for tapasin to perform this function. The coreTMD tapasin–binding site on TAP1 is poorly characterized, prompting Leonhardt et al. (p. 2480) to investigate where and how tapasin binds the coreTMD of TAP1 and whether this binding site is involved in stabilization of the TAP heterodimer. To do this, the authors performed mutagenesis of the six segments (TM5-TM10) of the coreTMD of TAP1 and stably expressed the mutants in human lymphoblastoid T2 cells. Immunoprecipitation of these mutants with an anti-TAP1 Ab revealed TM9 as the tapasin-binding domain in the coreTMD of TAP1. Further mutagenesis of TM9 identified six integral amino acids on the polar face required for tapasin binding. Mutating key residues in both the N-terminus and coreTMD of TAP1 determined that tapasin docking on both of these domains may be required to achieve full stability of TAP1 and subsequent stable heterodimer formation with TAP2. Together, these data suggest that all three tapasin-binding sites may cooperate to facilitate high transporter protein stability and efficient TAP heterodimerization.

  • Copyright © 2014 by The American Association of Immunologists, Inc.
PreviousNext
Back to top

In this issue

The Journal of Immunology: 192 (5)
The Journal of Immunology
Vol. 192, Issue 5
1 Mar 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In This Issue
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In This Issue
The Journal of Immunology March 1, 2014, 192 (5) 1995-1996; DOI: 10.4049/jimmunol.1490001

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In This Issue
The Journal of Immunology March 1, 2014, 192 (5) 1995-1996; DOI: 10.4049/jimmunol.1490001
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Modulating MAC in Traumatic Brain Injury
    • Supercharged Neutrophil Responses
    • E2A Fights Allelic Exclusion
    • IgA Helps NET Bacteria
    • Binding Potential TAPped
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Top Reads
  • In This Issue
  • In This Issue
Show more IN THIS ISSUE

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • Public Access
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2021 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606